Status
Conditions
Treatments
About
This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence of molecular alterations potentially involved in the mechanisms of resistance to antineoplastic treatment on breast and ovarian tumor tissue.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
10 participants in 1 patient group
Loading...
Central trial contact
IDA PARIS, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal